<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Clarity Pharmaceuticals Ltd — News on 6ix</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd</link>
<description>Latest news and press releases for Clarity Pharmaceuticals Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 13:02:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/clarity-pharmaceuticals-ltd" rel="self" type="application/rss+xml" />
<item>
<title>Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/clarity-signs-a-commercial-manufacturing-agreement-for-cu-64-sar-bispsma-with-nucleus-radiopharma</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/clarity-signs-a-commercial-manufacturing-agreement-for-cu-64-sar-bispsma-with-nucleus-radiopharma</guid>
<pubDate>Tue, 14 Apr 2026 13:02:00 GMT</pubDate>
<description>Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for 64Cu-SAR-bisPSMA with Nucleus RadioPharma, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of tar</description>
</item>
<item>
<title>Clarity signs a Commercial Manufacturing Agreement</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/clarity-signs-a-commercial-manufacturing-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/clarity-signs-a-commercial-manufacturing-agreement</guid>
<pubDate>Tue, 14 Apr 2026 02:54:04 GMT</pubDate>
<description>Clarity signs a Commercial Manufacturing Agreement</description>
</item>
<item>
<title>Co-PSMA data published in the European Urology journal</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-data-published-in-the-european-urology-journal</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-data-published-in-the-european-urology-journal</guid>
<pubDate>Tue, 31 Mar 2026 12:58:00 GMT</pubDate>
<description>Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results from the Co-PSMA (NCT06907641)[1] investigator-initiated trial (IIT) are now published in European Urology[2], the official journal of the European Association of Urology (EAU) Congress 2026 with an impressive impact factor of 25.2.</description>
</item>
<item>
<title>Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/clarity-signs-a-large-scale-manufacturing-supply-agreement-for-copper-64-with-theragenics</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/clarity-signs-a-large-scale-manufacturing-supply-agreement-for-copper-64-with-theragenics</guid>
<pubDate>Wed, 25 Mar 2026 13:01:00 GMT</pubDate>
<description>Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics.</description>
</item>
<item>
<title>Clarity signs a large-scale Manufacturing Supply Agreement</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/clarity-signs-a-large-scale-manufacturing-supply-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/clarity-signs-a-large-scale-manufacturing-supply-agreement</guid>
<pubDate>Wed, 25 Mar 2026 02:45:05 GMT</pubDate>
<description>Clarity signs a large-scale Manufacturing Supply Agreement</description>
</item>
<item>
<title>Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-data-presented-at-eau-annual-congress-2026-with-manuscript-accepted-for-publication-in-the-european-urology-journal</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-data-presented-at-eau-annual-congress-2026-with-manuscript-accepted-for-publication-in-the-european-urology-journal</guid>
<pubDate>Tue, 17 Mar 2026 13:01:00 GMT</pubDate>
<description>Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results from the Co-PSMA (NCT06907641)[1] IIT were presented by Prof Louise Emmett (St Vincent's Hospital Sydney) in an oral session at EAU Congress 2026, Europe's largest urological conference, on the 16th March in London, UK[2]. The study data has als</description>
</item>
<item>
<title>Co-PSMA data presented</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-data-presented</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-data-presented</guid>
<pubDate>Tue, 17 Mar 2026 03:01:04 GMT</pubDate>
<description>Co-PSMA data presented</description>
</item>
<item>
<title>Registrational Phase III AMPLIFY trial: Target number of participants achieved</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/registrational-phase-iii-amplify-trial-target-number-of-participants-achieved</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/registrational-phase-iii-amplify-trial-target-number-of-participants-achieved</guid>
<pubDate>Tue, 10 Mar 2026 13:02:00 GMT</pubDate>
<description>Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Phase III AMPLIFY trial (NCT06970847)[1] has now consented in excess of the planned number of participants following strong demand for study participation at sites in the United States (US) and Australia. Consenting of new patients has stopped at all si</description>
</item>
<item>
<title>AMPLIFY trial - Target number of participants achieved</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/amplify-trial-target-number-of-participants-achieved</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/amplify-trial-target-number-of-participants-achieved</guid>
<pubDate>Tue, 10 Mar 2026 02:24:05 GMT</pubDate>
<description>AMPLIFY trial - Target number of participants achieved</description>
</item>
<item>
<title>Half Yearly Report and Accounts</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/half-yearly-report-and-accounts-75</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/half-yearly-report-and-accounts-75</guid>
<pubDate>Fri, 27 Feb 2026 04:09:20 GMT</pubDate>
<description>Half Yearly Report and Accounts</description>
</item>
<item>
<title>SECuRE trial update: Another participant with undetectable PSA & negative PSMA PET</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/secure-trial-update-another-participant-with-undetectable-psa-and-negative-psma-pet</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/secure-trial-update-another-participant-with-undetectable-psa-and-negative-psma-pet</guid>
<pubDate>Mon, 23 Feb 2026 14:01:00 GMT</pubDate>
<description>Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that yet another participant with mCRPC in the Cohort Expansion Phase (Phase II) of the SECuRE trial achieved undetectable PSA and negative PSMA PET. The undetectable PSA was measured following the first cycle and the negative PSMA PET was reported following the</description>
</item>
<item>
<title>SECuRE trial update</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/secure-trial-update</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/secure-trial-update</guid>
<pubDate>Mon, 23 Feb 2026 03:21:03 GMT</pubDate>
<description>SECuRE trial update</description>
</item>
<item>
<title>Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-cu-64-sar-140300301</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-cu-64-sar-140300301</guid>
<pubDate>Mon, 16 Feb 2026 14:03:00 GMT</pubDate>
<description>Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the release of an abstract on the Co-PSMA (NCT06907641)[1] IIT, accepted for oral presentation at the upcoming EAU Congress 2026, Europe's largest urological conference, to be held from 13 to 16 March 2026 in London, UK[2]. The abstract outlines key findings fro</description>
</item>
<item>
<title>Co-PSMA abstract released</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-abstract-released</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-abstract-released</guid>
<pubDate>Mon, 16 Feb 2026 04:03:14 GMT</pubDate>
<description>Co-PSMA abstract released</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-7</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-7</guid>
<pubDate>Fri, 30 Jan 2026 05:11:04 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/secure-trial-continue-no-modifications-140200415</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/secure-trial-continue-no-modifications-140200415</guid>
<pubDate>Thu, 15 Jan 2026 14:02:00 GMT</pubDate>
<description>Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to share a number of updates on the SECuRE trial following an SRC meeting. The SRC has recommended that the trial continue with the Cohort Expansion Phase (Phase II) as planned with no modifications to the protocol. The interim results assessed by the SRC were collected fro</description>
</item>
<item>
<title>SECuRE trial to continue with no modifications to protocol</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/secure-trial-to-continue-with-no-modifications-to-protocol</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/secure-trial-to-continue-with-no-modifications-to-protocol</guid>
<pubDate>Thu, 15 Jan 2026 04:07:05 GMT</pubDate>
<description>SECuRE trial to continue with no modifications to protocol</description>
</item>
<item>
<title>Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-abstract-accepted-oral-140200252</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-abstract-accepted-oral-140200252</guid>
<pubDate>Wed, 24 Dec 2025 14:02:00 GMT</pubDate>
<description>Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an abstract on the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT), led by Prof Louise Emmett at St Vincent's Hospital Sydney, for oral presentation at the upcoming European Association of Urology (EAU) Congress 2026, Europe's bigge</description>
</item>
<item>
<title>Co-PSMA abstract accepted for oral presentation at EAU</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-abstract-accepted-for-oral-presentation-at-eau</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/co-psma-abstract-accepted-for-oral-presentation-at-eau</guid>
<pubDate>Wed, 24 Dec 2025 04:23:13 GMT</pubDate>
<description>Co-PSMA abstract accepted for oral presentation at EAU</description>
</item>
<item>
<title>Positive guidance from the US FDA on Cu-64 SARTATE Phase III</title>
<link>https://6ix.com/company/clarity-pharmaceuticals-ltd/news/positive-guidance-from-the-us-fda-on-cu-64-sartate-phase-iii</link>
<guid isPermaLink="true">https://6ix.com/company/clarity-pharmaceuticals-ltd/news/positive-guidance-from-the-us-fda-on-cu-64-sartate-phase-iii</guid>
<pubDate>Mon, 22 Dec 2025 03:39:17 GMT</pubDate>
<description>Positive guidance from the US FDA on Cu-64 SARTATE Phase III</description>
</item>
</channel>
</rss>